C4X Discovery signs potential $402mln deal | News Direct

C4X Discovery signs potential $402mln deal

C4X Discovery Holdings PLC
Digital Asset Direct by C4X Discovery Holdings PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | November 28, 2022 09:30 AM Eastern Standard Time

C4X Discovery Holdings CEO Clive Dix and chief business officer Bhavna Hunjan speak to Proactive after announcing an exclusive global licence deal with AstraZeneca to develop and commercialise C4X Discovery's NRF2 activator programme. The deal may ultimately be worth up to $402mln to the drug discovery company, and is structured to provide C4X Discovery with another steady stream of income.


Contact Details




Proactive UK Ltd


+44 20 7989 0813



project media


HealthPharma & BiotechDrug DiscoveryAstraZeneca